Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

It is sold in two forms - Mounjaro and Zepbound - by United States (US ... Mounjaro is sold in pens containing 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg doses. Each pen contains a single-use dose and ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

Zepbound is a GLP-1 agonist containing tirzepatide ... and 3.2% (with diabetes). Starting dose: 2.5 mg weekly, increasing to 5 mg after 4 weeks. Doses may continue to increase to a maximum ...

also called a Zepbound pen. The vial doses available are 2.5 mg and 5 mg, which is limited compared to the six Zepbound pen doses. Single-dose vials may be less convenient than an auto-injector pen.